Mast Cell Activation Syndrome.

Area of Science:

• Immunology
• Allergy
• Internal Medicine

Background:

• Mast cell activation syndrome (MCAS) affects multiple organ systems including skin, gastrointestinal, cardiovascular, respiratory, and neurologic systems.
• MCAS is classified into primary, secondary, and idiopathic subtypes.
• Diagnosis traditionally involved episodic symptoms affecting multiple organ systems, mediated by mast cells.

Purpose of the Study:

• To review and clarify diagnostic criteria for Mast Cell Activation Syndrome (MCAS).
• To highlight the spectrum of MCAS disorders, including symptoms, diagnostic tests, and treatments.
• To incorporate recent global classifications for MCAS diagnosis.

Main Methods:

• Review of earlier diagnostic criteria for MCAS.
• Inclusion of laboratory data, including serum tryptase and urinary metabolites (histamine, PGD2).
• Consideration of response to anti-mediator therapy (H1/H2 antagonists, anti-leukotrienes, mast cell stabilizers).

Main Results:

• Earlier criteria included specific symptoms like urticaria, flushing, GI distress, and respiratory issues.
• Laboratory confirmation involved elevated mast cell mediators (e.g., tryptase, histamine, PGD2) above baseline.
• A recent global classification emphasizes clinical symptoms, mediator increase, and response to treatment.

Conclusions:

• MCAS diagnosis requires a combination of clinical symptoms, elevated mast cell mediators, and therapeutic response.
• The concept of a "spectrum of MCAS disorders" aids in understanding and managing the condition.
• Updated diagnostic approaches integrate symptom patterns, objective laboratory findings, and treatment efficacy.